Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin domain family 3 member B (CLEC3B)
- Target
- CLEC3B
- Molecular classification
- C-type lectin, Soluble protein, Plasminogen-binding protein, Extracellular matrix-associated protein
01
Overview
C-type lectin domain family 3 member B (CLEC3B), commonly known as tetranectin, is a soluble extracellular protein primarily secreted by hepatocytes and connective tissue cells. It contains a single C-type lectin-like domain, binds to plasminogen, and enhances its activation via tissue plasminogen activator, promoting extracellular matrix remodeling and fibrinolysis. CLEC3B is involved in bone regeneration, tissue repair, modulation of angiogenesis, and immune function. Decreased levels of CLEC3B are associated with tumor progression and poorer prognosis in several cancer types, and certain variants are linked to macular-retinal dystrophy and longevity traits in some populations. CLEC3B is emerging as a multifunctional protein of interest as a disease biomarker and a potential therapeutic target, although no direct clinical drugs currently target CLEC3B.
- Other names
- TetranectinTNATNPlasminogen kringle 4-binding proteinMCDR4CLEC3Btetranectin (plasminogen-binding protein)
02
Mechanism of action
Not established for direct-acting drugs; possible mechanisms for drugs targeting the CLEC3B pathway include modulation of extracellular matrix turnover, inhibition or promotion of plasminogen activation, and immunomodulation
03
Biological functions
Extracellular proteolysis (plasminogen binding and activation)Bone mineralizationTissue remodelingModulation of tissue plasminogen activator-mediated plasminogen activationImmune regulationModulation of angiogenesisCardioprotection (via PI3K/Akt pathway)
04
Disease associations
Cancer (tumor progression, prognosis biomarker in hepatocellular carcinoma, clear cell renal cell carcinoma, ovarian/lung cancer)OsteoarthritisRetinal macular dystrophy (macular-retinal dystrophy)Cardiovascular disease (cardioprotection under hypoxic conditions)Aging/longevity (missense variants linked in some populations)
05
Safety considerations
None specifically documented for direct targeting; as with proteins involved in fibrinolysis, hypothetical risks include altered coagulation, bleeding, or impaired tissue repair
06
Interacting drugs
None specifically FDA-approved or widely recognized; ongoing research on recombinant proteins (therapeutic proteins like modified tissue plasminogen activator (tPA/tenecteplase) are relevant to its pathway, but not as direct CLEC3B binders)
07
Biomarkers
CLEC3B expression (serum/tissue) as diagnostic/prognostic biomarker in hepatocellular carcinoma, renal cell carcinoma, lung cancer, ovarian cancer, and macular-retinal dystrophy
Beyond the preview
Go deeper on C-type lectin domain family 3 member B (CLEC3B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-type lectin domain family 3 member B (CLEC3B).